Article

The efficacy of DNA MMR enzyme immunohistochemistry as a screening test for hypermutated gliomas

2019-11-15

Abstract excerpt

<h4>ABSTRACT</h4> A subset of gliomas has DNA repair defects that lead to hypermutated genomes. While such tumors are resistant to alkylating chemotherapies, they may also express more mutant neoantigens on their cell surfaces, and thus be more responsive to immunotherapies. A fast, inexpensive method of screening for hypermutated gliomas would therefore be of great clinical value. Since immunohistochemistry (IHC)...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 98645efb-7808-5756-8f17-8d7699416319
DOI: 10.1101/19012005

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The efficacy of DNA MMR enzyme immunohistochemistry as a screening test for hypermutated gliomasDOI 10.1101/19012005Read

The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomasSemantic proximity Read

Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter StudySemantic proximity Read

Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutationsSemantic proximity Read

Hypermutation as a Potential Predictive Biomarker of Immunotherapy Efficacy in High-Grade Gliomas: A Broken Dream?Semantic proximity Read

Mechanisms and therapeutic implications of hypermutation in gliomas.Semantic proximity Read

MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade gliomaSemantic proximity Read

The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.Semantic proximity Read

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.Semantic proximity Read

Hypermutations in gliomas: a potential immunotherapy target.Semantic proximity Read

The role of MGMT testing in clinical practice: a report of the association for molecular pathology.Semantic proximity Read

Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse GliomasSemantic proximity Read

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.Semantic proximity Read